[go: up one dir, main page]

EE200000536A - Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks - Google Patents

Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks

Info

Publication number
EE200000536A
EE200000536A EEP200000536A EEP200000536A EE200000536A EE 200000536 A EE200000536 A EE 200000536A EE P200000536 A EEP200000536 A EE P200000536A EE P200000536 A EEP200000536 A EE P200000536A EE 200000536 A EE200000536 A EE 200000536A
Authority
EE
Estonia
Prior art keywords
methods
pharmaceutical compositions
therapeutic agents
systemic action
oral vaccines
Prior art date
Application number
EEP200000536A
Other languages
English (en)
Inventor
Simpson Lance
Kiyatkin Nikita
Maksymowych Andrew
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EE200000536A publication Critical patent/EE200000536A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/832Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000536A 1997-10-20 1998-10-16 Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks EE200000536A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
PCT/US1998/021897 WO1999020306A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (1)

Publication Number Publication Date
EE200000536A true EE200000536A (et) 2002-04-15

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000536A EE200000536A (et) 1997-10-20 1998-10-16 Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks

Country Status (16)

Country Link
US (1) US6051239A (et)
EP (1) EP1024827B1 (et)
JP (1) JP2001522783A (et)
KR (1) KR100594787B1 (et)
CN (1) CN1246038C (et)
AT (1) ATE355076T1 (et)
AU (1) AU756475B2 (et)
BR (1) BR9815255A (et)
CA (1) CA2306995A1 (et)
DE (1) DE69837209T2 (et)
EE (1) EE200000536A (et)
HU (1) HUP0101017A3 (et)
IL (1) IL135743A (et)
NZ (1) NZ504549A (et)
RU (1) RU2227042C2 (et)
WO (1) WO1999020306A1 (et)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
EP1253932B1 (en) * 2000-02-08 2005-04-27 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CA2428270C (en) * 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
ATE426408T1 (de) * 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
EP2192172B1 (en) 2003-02-03 2014-12-03 iBio, Inc. System for expression of genes in plants
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
ES2532609T3 (es) * 2004-02-20 2015-03-30 Ibio, Inc. Sistemas y métodos para expresión clonales en plantas
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
DK1931379T3 (da) 2005-10-07 2013-08-19 Sec Dep For Health Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme
KR20110126726A (ko) 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
EP2155883A1 (en) * 2007-05-30 2010-02-24 Wyeth LLC Raccoon poxvirus expressing genes of feline antigens
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP2016513082A (ja) 2013-01-28 2016-05-12 ニューヨーク・ユニバーシティ 無毒性神経毒誘導体を用いる治療方法
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CA2969463A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
RU2020123346A (ru) 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для лечения расстройств, связанных с фиброзом

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
DE69535530D1 (de) * 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Also Published As

Publication number Publication date
EP1024827A4 (en) 2002-08-28
BR9815255A (pt) 2001-12-26
CN1246038C (zh) 2006-03-22
DE69837209T2 (de) 2007-10-31
US6051239A (en) 2000-04-18
DE69837209D1 (de) 2007-04-12
HUP0101017A3 (en) 2003-11-28
RU2227042C2 (ru) 2004-04-20
IL135743A0 (en) 2001-05-20
KR100594787B1 (ko) 2006-07-03
KR20010031236A (ko) 2001-04-16
CN1290174A (zh) 2001-04-04
AU1094799A (en) 1999-05-10
NZ504549A (en) 2002-12-20
JP2001522783A (ja) 2001-11-20
EP1024827B1 (en) 2007-02-28
CA2306995A1 (en) 1999-04-29
HUP0101017A2 (hu) 2001-07-30
EP1024827A1 (en) 2000-08-09
WO1999020306A1 (en) 1999-04-29
AU756475B2 (en) 2003-01-16
ATE355076T1 (de) 2006-03-15
IL135743A (en) 2004-03-28

Similar Documents

Publication Publication Date Title
EE200000536A (et) Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks
RU2000112547A (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ES2084360T3 (es) Formulaciones de aerosoles exentas de clorofluorocarbonos.
PT1121104E (pt) Novas formulacoes orais de libertacao controlada
ID29158A (id) Monoester probukol untuk pengobatan penyakit kardiovaskular dan peradangan
MD990262A (en) Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease
BR0210628A (pt) Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
NO981746L (no) Utlevering av biologisk aktive polypeptider
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DZ2461A1 (fr) Dérivés d'arylkylamines nouveaux et composition pharmaceutiques les contenant.
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
BG106221A (bg) Назални фармацевтични препарати съдържащи морфин и методи на приложението им
FI920206A0 (fi) Medicinsk anvaendning, medicinskt foerfarande och preparat.
CY1114734T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης
AR034343A1 (es) Combinaciones farmaceuticas
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
EP1080225A4 (en) COMPOSITIONS AND METHODS FOR THE PULMONAL ADMINISTRATION OF NUCLEIC ACIDS
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
EP0687728A3 (en) Reovirus strain 2177 and vaccine containing it
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht